Research Topics
| Mohamed SorrorSummaryAffiliation: Fred Hutchinson Cancer Research Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbiditiesMohamed L Sorror
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, WA 98109, USA
Blood 104:961-8. 2004..After adjustment for pretransplantation differences between the 2 patient groups, the hazard ratio was 3.0 (P=.04). Multivariate analyses showed higher pretransplantation comorbidity scores to result in increased toxicity and mortality...- Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphomaAndrew R Rezvani
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, MS D1 100, Seattle, WA 98109, USA
J Clin Oncol 26:211-7. 2008..Few effective treatment options exist for chemotherapy-refractory indolent or transformed non-Hodgkin's lymphoma (NHL). We examined the outcome of nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) in this setting... - Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantationMohamed L Sorror
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
J Clin Oncol 25:4246-54. 2007..Refined risk stratification is required to design prospective trials... 
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignanciesMohamed L Sorror
Transplantation Biology Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
JAMA 306:1874-83. 2011..A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions...
Comorbidities and hematopoietic cell transplantation outcomesMohamed L Sorror
Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, WA 98109, USA
Hematology Am Soc Hematol Educ Program 2010:237-47. 2010..Future knowledge of the impacts of multiple comorbidities on post-HCT toxicities might guide new prophylactic and therapeutic interventions to lessen the procedure's mortality...- Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiencesMohamed L Sorror
Fred Hutchinson Cancer Research Center FHCRC, Seattle, WA 98109 1024, USA
Blood 110:4606-13. 2007..98, P = .94). The HCT-CI is a sensitive and informative tool for comparing trial results at different institutions. Inclusion of comorbidity data in HCT trials provides valuable, independent information... - Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemiaMohamed L Sorror
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
Blood 111:446-52. 2008..01). Patients without comorbidities could be enrolled in prospective randomized studies comparing different conditioning intensities. Younger patients with comorbidities might benefit from reduced conditioning intensity... - Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningMohamed L Sorror
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
J Clin Oncol 26:4912-20. 2008..Here, we have extended the follow-up to a median of 5 years and have included data on an additional 18 patients... - Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantationMohamed Sorror
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Cancer 112:1992-2001. 2008..Herein, a recently developed HCT-specific comorbidity index (HCT-CI) was compared with a widely acceptable measure of health status, the Karnofsky performance status (KPS)... - Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantationFrederic Baron
Fred Hutchinson Cancer Research Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98109 1024, USA
J Clin Oncol 24:4150-7. 2006..Although most studies showed relatively low nonrelapse mortality (NRM) rates and encouraging short-term results, it has yet to be defined which patients would benefit most from these approaches... - Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experienceAndrew R Rezvani
Transplantation Biology Program, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
Br J Haematol 143:395-403. 2008..Non-myeloablative allogeneic HCT can produce long-term disease-free survival in patients with chemosensitive relapsed DLBCL who have failed or are ineligible for autologous HCT... - Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allograftsBoglarka Gyurkocza
Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 15:1314-22. 2009..We concluded that graft rejection after allogeneic HCT could be overcome by salvage transplantation using conditioning with Flu and low-dose TBI... - Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioningFrederic Baron
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
J Clin Oncol 23:1993-2003. 2005..This approach relied on graft-versus-tumor (GVT) effects for control of malignancy... - Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemiaMohamed L Sorror
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1-100, PO Box 19024, Seattle, WA 98109-1024, USA
J Clin Oncol 23:3819-29. 2005..CONCLUSION: CLL is susceptible to graft-versus-leukemia effects, and allogeneic HCT after nonmyeloablative conditioning might prolong median survival for patients with advanced CLL... - Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiationFrederic Baron
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 12:813-7. 2006..Additional immunosuppression with pentostatin did not improve that outcome. The model might be useful in developing potential strategies aimed at preventing graft rejection in patients with low donor chimerism levels... - Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemiaDaniella M B Kerbauy
Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 13:355-65. 2007..04), and decreased comorbidity score (P = .03) remained statistically significant for improved survival. Our findings show that hematopoietic cell transplantation offers potentially curative treatment for patients with ICMF, PV, or ET... - Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDSH Joachim Deeg
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
Blood 120:1398-408. 2012..Although mortality declined significantly in recent years, novel strategies are needed to overcome the barrier of high-risk cytogenetics... - Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allograftingMarcello Rotta
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 113:3383-91. 2009..03 and P = .02) and PFS (P = .04 and P = .03), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS only (P = .005). Long-term disease control and GVHD remain key issues... - Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemiaDaniella M B Kerbauy
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Biol Blood Marrow Transplant 11:713-20. 2005..D. Anderson prognostic score. The data suggest that patients with few or no comorbidities and those who undergo transplantation earlier in the disease course have the highest probability of successful outcome after allogeneic HCT... - What role is there for antithymocyte globulin in allogeneic nonmyeloablative canine hematopoietic cell transplantation?Razvan Diaconescu
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 11:335-44. 2005..82 (P = .09). We concluded that administering ATG before an otherwise suboptimal conditioning dose of 1 Gy of TBI failed to secure uniform stable hematopoietic engraftment... - Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donorsRazvan Diaconescu
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, WA 98109-1024, USA
Blood 104:1550-8. 2004..In conclusion, nonmyeloablative regimens had lower RRT and NRM and could be considered for comparative studies, including younger patients with more favorable Charlson comorbidity scores... - Reduced mortality after allogeneic hematopoietic-cell transplantationTed A Gooley
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
N Engl J Med 363:2091-101. 2010..Over the past decade, advances have been made in the care of patients undergoing transplantation. We conducted a study to determine whether these advances have improved the outcomes of transplantation... - Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomasAndrei R Shustov
University of Washington, Seattle, WA, USA
Br J Haematol 150:170-8. 2010..These results suggest that graft-versus-T-cell lymphoma activity is responsible for long-term disease control... - Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemiaRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
J Clin Oncol 29:1190-7. 2011..Hitherto, little attention has been given to the prognostic impact of pretransplantation minimal residual disease (MRD)... - Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myelomaGeorge E Georges
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, Seattle, WA 98109, USA
Biol Blood Marrow Transplant 13:423-32. 2007.... - Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTMohamed L Sorror
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, WA 98109-1024, USA
Blood 106:2912-9. 2005..In conclusion, the new simple index provided valid and reliable scoring of pretransplant comorbidities that predicted nonrelapse mortality and survival. This index will be useful for clinical trials and patient counseling before HCT... - Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimenH Joachim Deeg
Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 12:573-84. 2006.... - Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donorsMarco Mielcarek
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 13:1499-507. 2007..We conclude that within the limitations of a retrospective study, these results indicate that candidates for nonmyeloablative HCT without suitable related donors may expect similar outcomes with grafts from URDs... - Intensified postgrafting immunosuppression failed to assure long-term engraftment of dog leukocyte antigen-identical canine marrow grafts after 1 gray total body irradiationMohamed L Sorror
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Transplantation 85:1023-9. 2008..Late graft rejection after conditioning with 1 Gy of total body irradiation (TBI) was consistently seen in historical dogs given two postgrafting immunosuppressive drugs... - The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantationZejing Wang
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
Br J Haematol 149:101-10. 2010..ABO incompatibility did not affect nonmyeloablative HCT outcomes... - Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapyAjay K Gopal
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195, USA
Biol Blood Marrow Transplant 12:697-702. 2006..The rationale for incorporation of radioimmunotherapy into reduced intensity allogeneic transplantation regimens for non-Hodgkin lymphoma is discussed, as are current study designs, preliminary results, and future directions... - Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemiaMohamed L Sorror
Biol Blood Marrow Transplant 11:814-5. 2005 - Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantationChirag R Parikh
University of Colorado Health Sciences Center, Denver, CO 80262, USA
Am J Kidney Dis 45:502-9. 2005..The present study compares the incidence of ARF between patients undergoing concurrent myeloablative and nonmyeloablative HCT in the same period at the same institution... - Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioningFrederic Baron
University of Liege, Liege, Belgium
Biol Blood Marrow Transplant 13:1041-8. 2007..08 compared to the historical patients). We conclude that postgrafting immunosuppression with extended MMF and shortened CSP failed to decrease the incidence of GVHD among unrelated PBSC recipients given nonmyeloablative conditioning... - Re: Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host diseaseMohamed L Sorror
Biol Blood Marrow Transplant 11:567-8. 2005
Research Grants
- Impact of Comorbidities on Outcomes of Allogeneic TransplantationMohamed Sorror; Fiscal Year: 2007..End of Abstract) ..